Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.61
-0.06 (-0.69%)
May 26, 2026, 4:00 PM EDT - Market closed

Kyverna Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-156.4-161.31-127.48-60.37-28.89-26.35
Depreciation & Amortization
1.651.82.131.711.050.59
Stock-Based Compensation
11.0910.088.362.220.930.25
Other Adjustments
-2.56-3.21-5.120.611.137.85
Changes in Accounts Payable
3.030.540.744.080.680.01
Changes in Accrued Expenses
-2.811.8112.984.06-1.372.53
Changes in Unearned Revenue
-----7.03-5.66
Changes in Other Operating Activities
-2.01-3.43-5.86-4.72-2.61-1.37
Operating Cash Flow
-150.39-153.71-114.25-52.41-36.11-22.16
Capital Expenditures
-0-0.01-2.21-0.62-0.77-1.29
Sale of Property, Plant & Equipment
-0.07----
Purchases of Intangible Assets
-1.03-1.13----
Purchases of Investments
-399.4-364.62-490-54.85-56.5-
Proceeds from Sale of Investments
384.7405.7331.346.6843.17-
Investing Cash Flow
-15.7640.02-160.9-8.79-14.1-1.29
Long-Term Debt Issued
-24.7----
Net Long-Term Debt Issued (Repaid)
-24.7----
Issuance of Common Stock
101.2117.9341.430.650.180.03
Repurchase of Common Stock
-0.33-0.14----
Net Common Stock Issued (Repurchased)
100.86117.75341.430.650.180.03
Issuance of Preferred Stock
---59.911.9572.53
Net Preferred Stock Issued (Repurchased)
---59.911.9572.53
Other Financing Activities
-1.02-1.28-4.32-2.43-0.25-0.04
Financing Cash Flow
141.48141.17337.1158.1211.8872.52
Net Cash Flow
-24.6827.4761.96-3.08-38.3349.08
Free Cash Flow
-150.4-153.72-116.46-53.03-36.88-23.44
FCF Margin
-----525.00%-414.50%
Free Cash Flow Per Share
-3.10-3.47-3.04-78.73-80.97-0.09
Levered Free Cash Flow
-156.54-135.89-119.69-55.86-38.94-31.54
Unlevered Free Cash Flow
-163.93-169.11-134.82-57.9-39.43-31.54
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q